Samantha Perkins
Psychiatric/Mental Health · Anaheim, CANPI 1790023281
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $35,672 of the $48,962 with a category attached, or 72.9%. Teva Pharmaceuticals USA, Inc. accounts for 94.6% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $32,275, more than ten times the $106 reported in 2021. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 334 payments — averaging $146.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$46K
- Alkermes, Inc.$652
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$480
- Johnson & Johnson$456
- Otsuka America Pharmaceutical, Inc.$313
- E.r. Squibb & Sons, L.L.C.$186
- plus $536 from 7 others
What the payments were for
- Speaking & faculty fees$35,67273%
- Travel & lodging$4,87310%
- Food & beverage$8,19617%
- Education$2210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 228 | $46,339 |
| Alkermes, Inc. | 38 | $652 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $480 |
| Johnson & Johnson | 19 | $456 |
| Otsuka America Pharmaceutical, Inc. | 10 | $313 |
| E.r. Squibb & Sons, L.L.C. | 13 | $186 |
| Idorsia Pharmaceuticals US Inc | 1 | $105 |
| Axsome Therapeutics, Inc. | 1 | $101 |
| Luye Pharma (USA) Ltd. | 5 | $99 |
| AbbVie | 4 | $89 |
| Indivior Inc. | 3 | $78 |
| Neuronetics, Inc. | 2 | $34 |
| Neurocrine Biosciences, Inc. | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$42,130
- CAPLYTA$363
- ABILIFY MAINTENA$119
- ABILIFY ASIMTUFII$119
- QUVIVIQ$105
- Auvelity$101
How this compares
$48,962 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clozapine | 17 | $612 |
| Divalproex Sodium | 12 | $185 |
| Olanzapine | 11 | $137 |
| Quetiapine Fumarate | 12 | $99 |
| Clonazepam | 12 | $69 |
| Trazodone Hcl | 11 | $58 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Anaheim
- Vanessa YanAnaheim$26K
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- Yvette ElpidioOrange$43K
- Sarah KoLos Angeles$34K
- Jonathan LlamasPasadena$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.